Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for PDR Requiring Vitrectomy
NCT00516464Phase 3Unknown
- Sponsor
- Retina Associates
- Start
- Aug 2007
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Retina Associates. Primary endpoint: Effect of ranibizumab on vitrectomy complications at 6 months. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT00516464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516464.